Glyburide Starting Dose
The recommended starting dose of glyburide is 2.5 to 5 mg daily, administered with breakfast or the first main meal, but patients at higher risk for hypoglycemia—including elderly patients, those with renal impairment, or debilitated individuals—should be started at 1.25 mg daily 1.
Standard Dosing for Adults
For most adults with type 2 diabetes initiating glyburide therapy:
- Start with 2.5 to 5 mg once daily with breakfast or the first main meal 1
- Titrate in increments of no more than 2.5 mg at weekly intervals based on blood glucose response 1
- Usual maintenance dose ranges from 1.25 to 20 mg daily 1
- Maximum daily dose is 20 mg 1
Critical Dose Adjustments for High-Risk Populations
Elderly Patients
Start at 1.25 mg daily 1. This is non-negotiable. Elderly patients are at substantially increased risk for prolonged, severe hypoglycemia with glyburide. Research demonstrates that patients as young as 68 years experienced prolonged hypoglycemia (lasting >12 hours despite treatment) at mean doses of only 6.7 mg daily, with some cases requiring continuous glucose infusion for over 60 hours 2. The risk is particularly pronounced within the first 7 days of treatment 2.
Patients with Renal Impairment
Glyburide use is not recommended in patients with significant renal disease 3. The ADA/KDIGO consensus explicitly states that glyburide should be avoided in chronic kidney disease 3. If absolutely necessary in mild renal impairment, start at 1.25 mg daily with extreme caution 1.
Debilitated Patients
Start at 1.25 mg daily 1. This includes patients with:
- Congestive heart failure (increased hypoglycemia risk) 2
- Hepatic disease (contraindicated in significant liver disease) 4
- Malnutrition or irregular meal patterns
Important Clinical Considerations
Hypoglycemia Risk Profile
Glyburide carries a significantly higher hypoglycemia risk compared to other sulfonylureas. In head-to-head comparison, glyburide was associated with an 8.63-fold increased risk of hospital encounters for hypoglycemia compared to modified-release gliclazide when used as monotherapy (1.58% vs 0.18%, number needed to harm = 71) 5. This risk persists even when combined with metformin (6.06-fold increased risk) 5.
Dosing Frequency
- Once-daily dosing is usually satisfactory for doses ≤10 mg 1
- Twice-daily dosing may provide better response for doses >10 mg 1
- Approximately 75% of patients can be controlled with once-daily glyburide dosing 6
Drug Interactions
Administer glyburide at least 4 hours before colesevelam to avoid reduced absorption and decreased efficacy 1.
Common Pitfalls to Avoid
- Starting too high in the elderly: Even "standard" doses of 2.5-5 mg can cause severe, prolonged hypoglycemia in patients over 65-70 years
- Using glyburide in renal disease: This is explicitly contraindicated by current guidelines 3
- Ignoring the prolonged duration of action: Glyburide has a 7-10 hour half-life 7, meaning hypoglycemia can be protracted and difficult to manage
- Rapid titration: Never increase by more than 2.5 mg increments, and wait at least one week between adjustments 1
Alternative Considerations
Given glyburide's unfavorable safety profile, particularly regarding hypoglycemia risk 5 and lack of cardiovascular or renal protective benefits 8, 3, strongly consider alternative sulfonylureas (such as glimepiride or modified-release gliclazide) or other drug classes (SGLT2 inhibitors, GLP-1 receptor agonists) that offer superior safety and outcome benefits, especially in elderly patients or those with comorbidities.